Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Date:3/3/2010

aid-in capital 33,687 32,107 Accumulated deficit (866,541) (843,673) Accumulated other comprehensive income 46,825 38,954 ------------------------------------------------------------------------- Total shareholders' deficit (313,287) (299,873) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Total liabilities and shareholders' deficit $ 370,059 $ 385,197 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Forward Looking Statements --------------------------

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimates," "continues," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2010 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forw
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
3. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
4. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
5. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
6. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
7. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
8. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
9. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
10. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
11. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... company focused on the development of autologous cell ... Phase 1/2 clinical trial of RCT-01, being tested ... has been enrolled and their tissue biopsy sent ... is comprised of non-bulbar dermal sheath (NBDS) cells ...
(Date:6/29/2015)... ... ... This cutting edge standard making is a madatory tool for use in ... is the world’s first cuvette-shaped, solid-state filter that lets metrologists and quality control personnel ... calibration standards, such as those made from didymium glass were only able to operate ...
(Date:6/29/2015)... , June 29, 2015  AACC, a ... better health through laboratory medicine, is pleased to ... Clinical Chemistry , has increased to 7.9 ... This increase places Clinical Chemistry in ... reflects the significant influence of the research it ...
(Date:6/29/2015)... 2015   Veracyte, Inc . (Nasdaq: VCYT ... molecular cytology, today announced that it has been named ... list for the second year in a row. The ... an annual survey of Bay Area-company employees. ... to which Veracyte values our employees and their individual ...
Breaking Biology Technology:RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 2FireflySci Releases Spectrophotometer Calibration Standards for NIR Wavelength Accuracy Verification 3AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 2Veracyte Named a 2015 "Top Workplace" in the San Francisco Bay Area 3
... 22 Accelerated Community Oncology,Research Network (ACORN) ... and clinical trial network, announced today,that it ... of Business Development.,Webb brings a successful record ... has an exceptional background of work in ...
... Symbol: MS, - US$10 million received based on ... pivotal multiple sclerosis trial - EDMONTON, Sept. 22 ... in the treatment of multiple sclerosis (MS), today,announced that ... its,partner, Eli Lilly and Company., The milestone payment ...
... the Effects of Oral Calcitonin, a,combination of Salmon ... CEDAR KNOLLS, N.J., Sept. 22 Emisphere,Technologies, ... Novartis Pharma AG,and Nordic Bioscience have completed recruitment ... and efficacy of an oral formulation of,salmon calcitonin ...
Cached Biology Technology:ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development 2ACORN Contract Research Organization Appoints Tara Webb as Senior Director of CRO Business Development 3BioMS Medical announces receipt of milestone payment from Eli Lilly and Company 2Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment 2Emisphere Announces Recruitment Phase III Study for Oral Osteoarthritis Treatment 3
(Date:6/30/2015)... -- To bolster its efforts and commitment to fighting cyber ... addition of two new team members. ... David Raviv will act as head of strategic alliances. ... providing the most secure solutions for the enterprise market. ... Technologies, a provider of security and management products, which was ...
(Date:6/30/2015)... Genisphere announced Tom Bliss ... further develop Genisphere,s therapeutics capabilities and portfolio. Mr. Bliss ... much of the last 25 years in leadership positions ... Johnson & Johnson. Tom started his career in Investment ... Finance. He graduated from Dartmouth College with a BA ...
(Date:6/29/2015)... Research and Markets( http://www.researchandmarkets.com/research/zj7h4f/latin_america ) has ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Biomedical Sensors market is estimated at $0.65 billion by ... 2014-2020 The near future will bring Biomedical ... each individual. These sensors can be set to trigger ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... deadly 1918 Spanish influenza pandemic is why it struck ... such as St. Louis spared the fate of the ... health measures? What made the difference, according to two ... (NIH), was not only how but also how rapidly ...
... cell came from remain distinct even after the cell becomes ... in the February 1 issue of Cancer Research. , ... quest to understand the causes of childhood brain cancers, according ... O. Schnuck Family Professor of Neurology at Washington University School ...
... that the risk of HIV transmission may be highest ... a study published in the April 1 issue of ... infection accounted for nearly half of all transmission occurrences ... Canada. , Bluma Brenner, PhD, and Mark Wainberg, PhD, ...
Cached Biology News:Rapid response was crucial to containing the 1918 flu pandemic 2Rapid response was crucial to containing the 1918 flu pandemic 3Rapid response was crucial to containing the 1918 flu pandemic 4Genetic fingerprints identify brain tumors' origins 2Risk of HIV transmission highest early in infection 2
Competitors to lower non-specific signal...
... anti-rabbit IgG FITC is used as ... staining on tissues or culture cells ... in rabbits. It is highly recommended ... omitting the primary antibody, be included ...
Complete cell culture media with cytokines...
8 different frozen tissues are mounted on positively charged glass slides...
Biology Products: